Functional characterization of antibodies against Neisseria gonorrhoeae opacity protein loops.
BACKGROUND
The development of a gonorrhea vaccine is challenged by the lack of correlates of protection. The antigenically variable neisserial opacity (Opa) proteins are expressed during infection and have a semivariable (SV) and highly conserved (4L) loop that could be targeted in a vaccine. Here we compared antibodies to linear (Ab(linear)) and cyclic (Ab(cyclic)) peptides that correspond to the SV and 4L loops and selected hypervariable (HV(2)) loops for surface-binding and protective activity in vitro and in vivo.


RESULTS
Ab(SV cyclic) bound a greater number of different Opa variants than Ab(SV linear), including variants that differed by seven amino acids. Antibodies to the 4L peptide did not bind Opa-expressing bacteria. Ab(SV) (cyclic) and Ab(HV2) (cyclic), but not Ab(SV) (linear) or Ab(HV2 linear) agglutinated homologous Opa variants, and Ab(HV2BD) (cyclic) but not Ab(HV2BD) (linear) blocked the association of OpaB variants with human endocervical cells. Only Ab(HV2BD) (linear) were bactericidal against the serum resistant parent strain. Consistent with host restrictions in the complement cascade, the bactericidal activity of Ab(HV2BD) (linear) was increased 8-fold when rabbit complement was used. None of the antibodies was protective when administered vaginally to mice. Antibody duration in the vagina was short-lived, however, with <50% of the antibodies recovered 3 hrs post-administration.


CONCLUSIONS
We conclude that an SV loop-specific cyclic peptide can be used to induce antibodies that recognize a broad spectrum of antigenically distinct Opa variants and have agglutination abilities. HV(2) loop-specific cyclic peptides elicited antibodies with agglutination and adherence blocking abilities. The use of human complement when testing the bactericidal activity of vaccine-induced antibodies against serum resistant gonococci is also important.
Cole
Jessica G
JG
Department of Microbiology, F. Edward Hébert School of Medicine, Uniformed Services University of the Health Sciences, Bethesda, Maryland, United States of America.
Jerse
Ann E
AE
D000287:Administration, Topical; D000371:Agglutination / Q000187:drug effects; D000595:Amino Acid Sequence; D000818:Animals; D000900:Anti-Bacterial Agents / Q000494:pharmacology; D000907:Antibodies, Bacterial / Q000008:administration & dosage / Q000276:immunology* / Q000494:pharmacology; D000918:Antibody Specificity / Q000187:drug effects / Q000276:immunology; D001422:Bacterial Adhesion / Q000187:drug effects; D001425:Bacterial Outer Membrane Proteins / Q000737:chemistry* / Q000276:immunology*; D002462:Cell Membrane / Q000187:drug effects / Q000276:immunology; D002478:Cells, Cultured; D002584:Cervix Uteri / Q000166:cytology; D005260:Female; D006801:Humans; D051379:Mice; D008826:Microbial Sensitivity Tests; D008969:Molecular Sequence Data; D009344:Neisseria gonorrhoeae / Q000166:cytology / Q000187:drug effects / Q000276:immunology*; D017433:Protein Structure, Secondary; D013499:Surface Properties / Q000187:drug effects
D000900:Anti-Bacterial Agents; D000907:Antibodies, Bacterial; D001425:Bacterial Outer Membrane Proteins; C090348:Opa protein, Neisseria